Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells
about
Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevanceMesenchymal Stem Cell-Mediated Effects of Tumor Support or SuppressionInteraction between circulating cancer cells and platelets: clinical implicationEmerging roles of PDGF-D in EMT progression during tumorigenesisPancreatic cancer stem cells: emerging target for designing novel therapyMicroRNAs that affect prostate cancer: emphasis on prostate cancer in African AmericansActivated K-ras and INK4a/Arf deficiency cooperate during the development of pancreatic cancer by activation of Notch and NF-κB signaling pathwaysMolecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathwaysPlatelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts.Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cellsEpithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma.Periostin is up-regulated in high grade and high stage prostate cancer.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Platelet-derived growth factor-DD targeting arrests pathological angiogenesis by modulating glycogen synthase kinase-3beta phosphorylation.Role of receptor tyrosine kinases and their ligands in glioblastoma.Pancreatic cancer stem cells and EMT in drug resistance and metastasis.Emerging roles of PDGF-D signaling pathway in tumor development and progression.PDGF upregulates Mcl-1 through activation of β-catenin and HIF-1α-dependent signaling in human prostate cancer cells.Optical fiber-based in vivo quantification of growth factor receptors.The epigenetics of epithelial-mesenchymal plasticity in cancer.New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrenceHistone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressivenessmiR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells.Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cellsCell fusion between gastric epithelial cells and mesenchymal stem cells results in epithelial-to-mesenchymal transition and malignant transformationOver-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells.Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.Epithelial-mesenchymal transition in oral squamous cell carcinomaYBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment.Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasisMiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DDA comparison of epithelial-to-mesenchymal transition and re-epithelializationMarked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.
P2860
Q24628819-A2907313-406D-4AEB-9AAB-D6D4CCE1CDC4Q24646761-D24BBAD3-82EF-4664-9314-C581DE44C7C0Q26773413-0370FDCE-1F1D-42A5-8837-02D3EBDDEFFFQ26778920-7A38E96F-68A6-4EDB-A733-0EF070F9B96CQ26859634-A6A4FAEA-0864-4618-8853-D3AA2C0BB383Q26863365-CABA4F56-977E-4822-AF47-DDBF80E5C8C7Q27008271-2896AA1C-6CB9-43B2-A1CA-9D5454FECFB6Q28478427-BD21D50F-5176-484B-B610-9CD84C34CC69Q28749074-1792C391-D750-40DE-B0C2-8C4E46110447Q29347051-23C85E85-4896-4BBD-BC6E-3307E4F5AB7EQ30988612-8F3EBC67-97F3-4A4D-87ED-229FD1E4DCCEQ33351622-3DD27DA3-4074-49B0-9191-880F2EF5CBEAQ33395780-2CA28B88-8969-41D2-B6F6-2B0B945A50B0Q33598586-E1539AC1-4BAE-4BDC-B02A-F7AA5212653CQ33599377-EA5CD69D-EA04-4217-BE20-36DA630A01AFQ33775723-34007A89-8E01-4F32-99C1-95E83F84A2D9Q33832464-6496D14E-7E54-4475-AA29-1F920EF6BCA8Q33883849-6F86938A-CBE2-4DCE-A320-9B5E1B1A493AQ33886120-53C19090-7A65-42A4-A124-B28EDC0B2D99Q33912608-F910228B-3E3C-4F13-BB90-2F82E9A0B465Q34140712-0CF439D4-D4ED-4D6C-B46B-3DFFDE694B34Q34226408-641241AA-079C-4CF4-A58A-F0676F19B210Q34310378-A863567C-BA5F-498B-9F96-8DDF0793A3E8Q34382914-D723010C-8218-49C0-A2F6-B6F2315053D5Q34425201-DCF1604E-FC80-444D-94DE-1BF7C0FA4F75Q34734595-15C9B7A1-4544-448A-A085-728DC912A559Q34885299-88B9C78A-F4D1-45BF-BB6D-0B41043D3C87Q34988143-6B2A64CB-8922-4ADA-96AC-5321B8F02874Q35013660-BAF93A64-9C85-45F7-A2DA-E58C9C3BA5EEQ35052688-97267233-821E-480A-AB0E-C8BD7DA71C24Q35163008-D0FE9BF1-8198-4849-A69B-2F4385F68FF5Q35205677-DC6DBEAA-BAA7-4F6E-AA8C-0AD998E32F7CQ35740131-5EF61FA0-115D-4E2B-964C-56599878A4DCQ35884866-C3A6EAD8-D46F-479B-B1F5-2A03E03DFBF5Q35955424-1697A6A0-F7C5-42FF-8698-FD36152B7AE0Q36026661-FC2F8A48-9EEA-4A4E-8F7C-785F99FC0146Q36508613-00B43367-0F25-4F30-9B5E-33F52A6FE959Q36607541-68866ED7-E866-4CD0-9D9C-46DABDE83F27Q36678367-91157C4F-E2F9-45E9-81BF-7E5AAE55C313Q36746688-6675C3FD-65A0-47B8-ACF5-30485FF57DB8
P2860
Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Platelet-derived growth factor ...... n of PC3 prostate cancer cells
@en
Platelet-derived growth factor ...... of PC3 prostate cancer cells.
@nl
type
label
Platelet-derived growth factor ...... n of PC3 prostate cancer cells
@en
Platelet-derived growth factor ...... of PC3 prostate cancer cells.
@nl
prefLabel
Platelet-derived growth factor ...... n of PC3 prostate cancer cells
@en
Platelet-derived growth factor ...... of PC3 prostate cancer cells.
@nl
P2093
P2860
P1433
P1476
Platelet-derived growth factor ...... n of PC3 prostate cancer cells
@en
P2093
Allen Saliganan
Dejuan Kong
Fazlul H Sarkar
Hyeong-Reh Choi Kim
Michael L Cher
Sanjeev Banerjee
Sarah H Sarkar
Zhiwei Wang
P2860
P304
P356
10.1634/STEMCELLS.2007-1076
P577
2008-04-10T00:00:00Z